The duration of effect of SL75212 on an exercise tachycardia [proceedings]

Balnave, K; Neill, JD; Russell, CJ; Shanks, R. G.; Leahey, William J.; Wilson, Richard W.; Harran, DW

doi:10.1111/j.1365-2125.1980.tb04856.x

Brit J Clinical Pharma

1980

DOI: 10.1111/j.1365-2125.1980.tb04856.x

|View full text |Cite

The duration of effect of SL75212 on an exercise tachycardia [proceedings]

K Balnave¹,

JD Neill²,

CJ Russell³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1982

1989

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl ¹⁴C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Aubert¹,

Beaucourt²,

Pichat³

1982

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The h y n t h u h 06 (BETAXOLOL) Lab&ed w i t h m b o n 14 : I -[ 4 -( 2-cychptopyL methoxyethyL-[ 1 -1 4 C ] ) phenoxy]-3-hoptoyf &no-2pfiopawb : 13 wan achieved by a &&?.h? h t e p btgUeVICe @om [ C ] c a b o n dioxide. Cmbonation w i t h I4C02 06 t h e Ghignand heagent 1 gave 4-benzyLoxy benzoic a c i d : 2 ( 8 7 % y i e l d ) . 2 wan b~C C e A b i \ i & &&ed efi dokhtion wdh-diazomahane and U t k i w n aeUminiwn hydhide giving d e t o [ 7 -' 4 C ] 4-bcnzyLoxybenzyL d c o h o d 4 ( b 2 % y i d d ) . AdcohoL 4 WM &tamdomed i n t o xhe comenponding ckeohide 5 when expobed t o thionyLckeohide i n etheh. 5 WM condenbed w i t h NaCN i n DMF t o give t h e ni,t&Le 6 which w f i hycihoPyned i n t o t h e a c i d 7 h o d a t e d i n a 75 %

show abstract

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl ¹⁴C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Aubert¹,

Beaucourt²,

Pichat³

1982

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

Decreased Intraocular Pressure in the Hypertensive Human Eye With Betaxolol, a β1-Adrenergic Antagonist

Feghali

Kaufman

1985

American Journal of Ophthalmology

View full text Add to dashboard Cite

Betaxolol

FRACO¹

1989

Australian and New Zealand Journal of Ophthalmology

View full text Add to dashboard Cite

Drugs classified as beta-blockers have proved to be valuable in the treatment of patients with glaucoma. Timolol has become the most widely used ocular hypotensive agent. Actual and potential side effects associated with its non-selective beta-blockade have prevented its use in patients with reactive airways disease, and to a lesser extent, with various cardiovascular conditions. Betaxolol is a relatively selective beta-1 blocker which in most patients is almost as effective as timolol in lowering intraocular pressure, and may be partly additive with dipivefrin. It is probably safer in patients unable to tolerate non-selective beta-blockers. However, it needs to be used with caution in these patients, who are unpredictably susceptible to systemic side effects.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The duration of effect of SL75212 on an exercise tachycardia [proceedings]

Cited by 4 publications

References 1 publication

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl ¹⁴C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl ¹⁴C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Decreased Intraocular Pressure in the Hypertensive Human Eye With Betaxolol, a β1-Adrenergic Antagonist

Betaxolol

Contact Info

Product

Resources

About

The duration of effect of SL75212 on an exercise tachycardia [proceedings]

Cited by 4 publications

References 1 publication

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl 14C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl 14C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Decreased Intraocular Pressure in the Hypertensive Human Eye With Betaxolol, a β1-Adrenergic Antagonist

Betaxolol

Contact Info

Product

Resources

About

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl ¹⁴C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2

Synthese du SL 75.212 (Betaxolol) Marque au Carbone 14 : [Cyclopropylmethoxy‐2 Ethyl ¹⁴C‐1)‐4 Phenoxy] ‐ 1 Isopropylamino‐3 Propanol‐2